NCT03935347View on ClinicalTrials.gov

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 20, 2019

Primary Completion Date

May 1, 2022

Study Completion Date

May 1, 2023

Conditions
Metastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Ureter Urothelial CarcinomaMetastatic Urethral Urothelial CarcinomaUnresectable Renal Pelvis Urothelial CarcinomaUnresectable Ureter Urothelial Carcinoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

DRUG

Fludarabine Phosphate

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes LN-145

Given IV

BIOLOGICAL

Aldesleukin

Given IV

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors
All Listed Sponsors
collaborator

Iovance Biotherapeutics, Inc.

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER